Yuhan's Revanex has fared well in anti-ulcerant market

Published: 2008-03-10 06:59:00
Updated: 2008-03-10 06:59:00
With the renormalized distribution last week, Yuhan's novel proton inhibitor Revanex (revaprazan) is expanding its share of the domestic anti-ulcerant market.

Revanex' sales have exceeded the 10 billion won mark in just 12 months after Yuhan launched the drug last year. The company says Revane...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.